NCT04834440

Ropivacaine Use in Femoral Nerve Block; What is the Minimal Effective Analgesic Concentration (MEAC 90)

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 45 (estimated)
• Sponsor: Healthpoint Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to determine the minimal effective ropivacaine concentration required to provide adequate analgesic femoral nerve block in 90% of patients (MEAC90)

Detailed description

* Before induction of GA, all patients will receive sciatic, obturator, lateral femoral cutaneous and femoral nerve blocks. * The femoral nerve block will be performed using 15ml of ropivacaine which concentration relied on the response of the previous patient. * Based on biased-coin design up-down sequential method: when a patient has a negative response, the next patient will receive a concentration 0.01% w/v higher. However if he has a positive response, the next patient will be randomized to receive either the same ropivacaine concentration or a concentration 0.01% w/v less. * Patients with pain free recovery will be considered to have positive response. * Patients' responses will be analyzed to calculate the MEAC90

Conditions

• Postoperative Pain

Interventions

Type	Name	Description
DRUG	Ropivacaine	all patients will receive femoral nerve block using same volume of ropivacaine but in different concentrations

Timeline

• Start date: 2021-05-01
• Primary completion: 2021-09-30
• Completion: 2021-09-30
• First posted: 2021-04-08
• Last updated: 2021-04-08

Locations

1 site across 1 country: United Arab Emirates